The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status

Haematologica

Volumn 99, Issue 10, 2014, Pages 1605-1610

  Foglietta, Myriam ^a,b,c   Castella, Barbara ^a,b   Mariani, Sara ^a,c   Coscia, Marta ^a,b,c   Godio, Laura ^c,d   Ferracini, Riccardo ^c   Ruggeri, Marina ^a,c   Muccio, Vittorio ^a,c   Omedé, Paola ^a,c   Palumbo, Antonio ^a,c   Boccadoro, Mario ^a,c   Massaia, Massimo ^a,b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b Laboratorio di Ematologia Oncologica Centro di Ricerca in Medicina Sperimentale (CeRMS)   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR4; GAMMA INTERFERON; INTERLEUKIN 17; MACROPHAGE DERIVED CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; BIOPSY; CASE CONTROL STUDY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; PHENOTYPE;

BIOPSY; BONE MARROW; CASE-CONTROL STUDIES; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84907482094     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.105866     Document Type: Article

References (34)

1. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004; 18(1):139-45.
2. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer. 2010;127(4):748-58.
3. Lindqvist CA, Loskog AS. T regulatory cells in B-cell malignancy tumour support or kiss of death? Immunology. 2012;135(4):255-60.
4. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289-295.
5. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107(1):301-4.
6. Gupta R, Ganeshan P, Hakim M, Verma R, Sharma A, Kumar L. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res. 2011;35(7):874-78
7. + regulatory T cells in patients with multiple myeloma. Blood. 2006;107(10):3940-9.
8. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106(3):546-52.
9. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic Tcell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148.
10. +HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72(6):540-7.
11. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-) alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol. 2009;144(5):686-95.
12. Ostad M, Andersson M, Gruber A, Sundblad A. Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood. 2008;111(5):2725-32.
13. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T. regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077.
14. + T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008;93(3):423-30.
15. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al. Bone marrow and the control of immunity. Cell Mol Immunol. 2012; 9(1):11-9.
16. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVisionTM+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMateTM, CSA, LABC, and SABC technique. J Clin Pathol. 1998; 51:506-11.
17. Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, et al. Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Exp Hematol. 2009; 37(6):728-38.
18. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβCD8+ T cells, regulatory T cells, and dendritic cells. J Immunol. 2011;187(4):1578-90.
19. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M, et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after highdose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol. 2001;113(4):1051-9.
20. + regulatory T cells in peripheral blood are primarily of effector memory phenotype. J Clin Oncol. 2007; 25(18):2628-30; author reply 2630-2. Erratum in: J Clin Oncol. 2012;30(31):3903.
21. + regulatory T cells. J Exp Med. 2004;199(3):303-13.
22. Darrasse-Jèze G, Podsypanina K. How Numbers, Nature, and Immune Status of Foxp3+ Regulatory T-Cells Shape the Early Immunological Events in Tumor Development. Front Immunol. 2013;4:292.
23. + regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013; 110(44):17945-50.
24. Föhse L, Suffner J, Suhre K, Wahl B, Lindner C, Lee CW, et al. High TCR diversity ensures optimal function and homeostasis of Foxp3+ regulatory T cells. Eur J Immunol. 2011;41(11):3101-13.
25. Pacholczyk R, Kern J. The T-cell receptor repertoire of regulatory T cells. Immunology. 2008;125(4):450-8.
26. -T cells. J Immunol. 2007; 179(6):3412-6.
27. Gao Z, Gao Y, Li Z, Chen Z, Lu D, Tsun A, et al. Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation. Int J Clin Exp Pathol. 2012;5(7):626-33.
28. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007; 317(5835):256-60.
29. Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, et al. The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One. 2013;8(3):e58504.
30. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13(5):1503-10.
31. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108(8):2655-61.
32. Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma. 2012; 53(7):1406-8.
33. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 2011;71(22):6915-20.
34. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72(14):3439-4.